(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 1.83% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Amphastar Pharmaceuticals's revenue in 2025 is $730,659,000.On average, 3 Wall Street analysts forecast AMPH's revenue for 2025 to be $33,914,686,094, with the lowest AMPH revenue forecast at $33,741,214,261, and the highest AMPH revenue forecast at $34,128,697,540. On average, 3 Wall Street analysts forecast AMPH's revenue for 2026 to be $35,147,373,167, with the lowest AMPH revenue forecast at $34,222,975,710, and the highest AMPH revenue forecast at $35,704,557,152.
In 2027, AMPH is forecast to generate $36,368,086,912 in revenue, with the lowest revenue forecast at $34,477,526,769 and the highest revenue forecast at $38,089,323,462.